Topic
Drug Safety
548 published works
The Daily Intake
Federal Court Orders Gold Star Distribution to Correct Persistent Insanitary Conditions
On September 21, 2026, the U.S. District Court for the District of Minnesota ordered Minnesota-based Gold Star Distributions, Inc. and its owner to stop distributing FDA-regulated products until they comply…
Drug Injury Watch
Tavneos Liver Risks Confirmed by Medical Registry Data in the US
By Tom Lamb
Possible Legal Compensation Cases for People Who Developed Tavneos Liver Injury (Posted by Tom Lamb at Drug Injury Watch) We had been reporting on Tavneos liver risks earlier this year, as seen below:…
Searcy Law Blog
Labeling Defects: When Can You Sue a Drug Company for “Failure to Warn”?
By Searcy Law
Drug companies are required to include warnings about known health risks on all prescription and over-the-counter medications. If you or a loved one has been harmed by a medication that…
Drug & Device Law
Claims Can Still Be Preempted If The Drug Is Later Withdrawn
Long ago, it seemed that large-scale drug or device litigation was usually spurred on by a recall, market withdrawal, or major labeling change describing a new risk or limiting the…
Tortini
Acetaminophen – Distortion of Scientific Publication – Part 3
Both in acetaminophen litigation and in performative political assertion, the Prada Review has loomed large. As noted in an earlier post, one of the authors of the Prada Review was…
The Daily Intake
FDA Denies Request for Public Hearing on Repeal of Authorizations for FD&C Red No. 3
Today FDA rejected an objection and request for a public hearing on the Agency’s final order to repeal the color additive regulations for FD&C Red No. 3 when used in…
Searcy Law Blog
Gas-X Extra Strength Softgels Subject to Nationwide Recall Due to Contamination Concerns
By Searcy Law
Haleon, the manufacturer of Gas-X Extra Strength Softgels, has issued a voluntary recall for 120 count and 72 count bottles of 125mg capsules distributed from April 13, 2026 to May…
Drug & Device Law
The Eye of the Beholder: The Taxotere Warning Was Fine, But Don’t Tell That to This Court
We have written before about the Taxotere eye injury MDL — and we wish we could say things were getting better. They are not. Last December, we noted the fundamental…
Drug Injury Watch
Ozempic And Other GLP-1RA Use Associated With NAION Eye Side Effect
By Tom Lamb
New 2026 Medical Article Published By JAMA Network Open Investigates Drug Safety Issue (Posted by Tom Lamb at Drug Injury Watch) An increasingly known but still-developing drug safety issue is that of Ozempic…
Napoli Shkolnik Blog
Dupixent Cancer Risk: What Patients Need to Know About CTCL
Emerging Research Raises Questions About Dupixent’s Safety Profile Dupixent (dupilumab) has become one of the most widely prescribed biologic medications for chronic inflammatory conditions, helping over one million patients worldwide manage…